Related Experiment Video
Updated: May 5, 2026

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
HLA-B*51:01 in Iranian patients with Behcet uveitis syndrome
Zahra Hoseini1, Fatemeh Rezaei Rad1, Mohammad Zarei2
1Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background:
Behcet's disease (BD) is a multisystem disorder prevalent along the historic Silk Road, with Behcet's uveitis (BU) representing a significant complication contributing to disability. Various studies have linked different HLA alleles with BD across diverse populations.
Methods:
In this study, we investigated the association between HLA-B51:01/x and HLA-B27/x genotypes with Behcet's uveitis in 50 unrelated Iranian patients diagnosed with Behcet's uveitis, comparing them to a control group of 70 healthy individuals. Our analysis aimed to determine the susceptibility conferred by these alleles and assess their clinical relevance.
Results:
Our findings indicate a notable susceptibility conferred by the HLA-B51:01/x genotype for Behcet's uveitis (P=0.0001). Conversely, the B27/x genotype did not demonstrate significant associations with Behcet's uveitis. Furthermore, we employed prevalence-corrected positive predictive value (PcPPV) calculations to gauge the clinical utility of testing for these alleles within the Iranian Behcet's uveitis patient population. The PcPPV for B27/x genotype testing was determined to be 0.05%, while the PcPPV for B51:01/x genotype testing in the same population was 0.065%. These results suggest that carriers of the B*51:01 allele, when presenting with clinical symptoms, exhibit a heightened risk for Behcet's uveitis compared to the general population.
Conclusion:
Individuals carrying the B51:01 allele, when symptomatic, face an elevated Behcet's uveitis risk. This insight aids in targeted clinical assessments for at-risk populations.
More Related Videos
Related Concept Videos
Hepatitis
Graves' Disease I: Introduction
Inflammatory Bowel Disease IV: Clinical Manifestations

